MedPath

Investigating the Use of a Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy

Phase 2
Completed
Conditions
Bladder Cancer
Interventions
Dietary Supplement: high arginine nutritional supplement (Nestle's Impact AR)
Registration Number
NCT02655081
Lead Sponsor
University of Pittsburgh
Brief Summary

To provide patients with bladder cancer who are scheduled to undergo radical cystectomy with a preoperative high-arginine nutritional supplement. The investigator will measure patient adherence to the regimen, tolerability of the supplement and feasibility of supplementation. Secondary outcome measures will include differences in length of stay and complication rate between groups.

Detailed Description

The purpose of this study is to investigate the use of a high-arginine protein supplement prior to surgery for patients undergoing radical cystectomy for treatment of bladder cancer. As many as 50% of patients who undergo radical cystectomy experience a postoperative complication, and poor preoperative nutritional status is known to increase the risk of complications. Preoperative use of a high-arginine protein shake has been shown to reduce the risk of postoperative complications for patients undergoing surgery for colon cancer, and this study seeks to determine whether this is also true for patients undergoing radical cystectomy for bladder cancer.

Subjects will drink four protein shakes (Nestle Impact AR) per day for 5-7 days prior to radical cystectomy. Shakes will be provided to patients free of charge. On the date of surgery, subjects will turn in a log of shake consumption. Surgery will then proceed in typical fashion, and no changes will be made to surgery or postoperative care. Clinical outcomes for the first 90 postoperative days will be collected. Patient outcomes will be compared to those of contemporary controls who do not undergo supervised nutritional supplementation. Primary study outcome is to assess safety, tolerability and adherence to supplementation regimen. Secondary outcomes include differences in complication rates and length of postoperative hospital stay between groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Any adult patient seen at one of the aforementioned UPMC facilities who carries a diagnosis of bladder cancer and is considered a candidate for radical cystectomy for treatment.
Read More
Exclusion Criteria
  • Minors < 18 years of age, patients not considered surgical candidates, patients who do not go on to undergo radical cystectomy. Patients with Glomerular Filtration Rate (GFR) < 30 will also be excluded in an attempt to limit protein intake of patients with Stage IV and V Chronic Kidney Disease. Diabetic patients will be allowed to participate.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Dietary supplementhigh arginine nutritional supplement (Nestle's Impact AR)Subjects will receive high arginine nutritional supplement (Nestle's Impact AR), prior to cystectomy
Primary Outcome Measures
NameTimeMethod
Safety, tolerability and adherence to supplementation regimen."4 months

Investigator will report on any adverse events from supplementation as well as patient adherence to regimen.

Secondary Outcome Measures
NameTimeMethod
Incidence of 90-day overall and infectious complication rates. I4 months

Investigator will compare overall, infectious and wound complication rates between the study group and control group

Length of hospital stay between study group and control group4 months

The Investigator will compare the length of hospital stay between study group and control group.

Trial Locations

Locations (1)

Shadyside Urology

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath